Erudio Healtherudio.com
Drug
Blinatumomab trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying blinatumomab: A041703. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 5 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| A041703 NCT03739814 · National Cancer Institute (NCI) | CD22-positive B-lineage acute lymphoblastic leukemia | Phase 2 | 133 | 23 | Focused | Nov 9, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| E1910 NCT02003222 · National Cancer Institute (NCI) DeepView → | newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia | Phase 3 | Deep | View | |||
| AALL1731 NCT03914625 · National Cancer Institute (NCI) DeepView → | newly diagnosed standard-risk B-cell acute lymphoblastic leukemia | Phase 3 | Deep | View | |||
| Total XVII NCT03117751 · St. Jude Children's Research Hospital FocusedView → | Not given | Phase 2/Phase 3 | Focused | View | |||
| AALL1732 NCT03959085 · Children's Oncology Group FocusedView → | high-risk B-ALL, mixed phenotype acute leukemia, B-LLy | Phase 3 | Focused | View | |||
| AALL2131 NCT06124157 · National Cancer Institute (NCI) FocusedView → | Ph+ or ABL-class Ph-like B-cell acute lymphoblastic leukemia | Phase 2 | Focused | View | |||